Ann: Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited, page-21

Some companies can be written off entirely - BIT still has a possible saviour in the HIV field.

I think management is quite poor is several areas, However, with biotechs, anything remains a possibility.

I think BIT needs to make some hard decisions and it has, maybe, another 12 months to prove itself.

If its products have any real value, then interest from BP will come. If not, then maybe 12 months is all they have left. I'll take a glass half full approach at the moment. I am not going to invest in BIT without some major changes to management practices (addressing the funding issue and improvements to share holder communications) and goals being reached so I am taking a very cautious approach at the moment as well.